Benign Prostatic Hyperplasia Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – GemVax & KAEL, Urovant Sciences, and Ausio Pharma

Delveinsight Business Research LLP
DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Benign Prostatic Hyperplasia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Benign Prostatic Hyperplasia: An Overview

As per the National Institute of Diabetes and Digestive and Kidney Diseases, benign prostatic hyperplasia (BPH) is a noncancerous condition in men in which the prostate gland is enlarged. BPH is also called benign prostatic hypertrophy or benign prostatic obstruction. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. BPH often occurs with the second growth phase.

The treatment of BPH includes lifestyle changes, medications, minimally invasive procedures, and surgery.

Benign Prostatic Hyperplasia Market Key Facts

Among the 7MM, the most prevalent cases of Benign Prostatic Hyperplasia (BPH) were recorded in the United States.

As per a study conducted by Lim et al. (2017), the histological prevalence of Benign Prostatic Hyperplasia was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively.

A study conducted by Lee et al. (2017), titled “The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis,” showed that the median point prevalence of BPH was 25.2%.

According to the study by Lee et al., BPH is more common in older males as compared to those below 40 years. 

Benign Prostatic Hyperplasia Market

The key driver for the Benign Prostatic Hyperplasia (BPH) market is an increase in the cases of risk factors such as obesity, heart, and circulatory disease, type 2 diabetes, and a rise in the geriatric population. These factors, along with the expected launch of emerging therapies, will boost the Benign Prostatic Hyperplasia (BPH) market growth in the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Benign Prostatic Hyperplasia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Benign Prostatic Hyperplasia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Benign Prostatic Hyperplasia Epidemiology

The epidemiology section covers insights about the historical and current Benign Prostatic Hyperplasia patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched in the market during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market

Benign Prostatic Hyperplasia Therapeutics Analysis

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.

Benign Prostatic Hyperplasia (BPH) Companies:

GemVax & KAEL

Urovant Sciences

Ausio Pharmaceuticals

And many others.

Benign Prostatic Hyperplasia (BPH) Therapies covered in the report include:

GV1001

Vibegron

AUS-131 (S-equo)

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Benign Prostatic Hyperplasia Competitive Intelligence Analysis

4. Benign Prostatic Hyperplasia Market Overview at a Glance

5. Benign Prostatic Hyperplasia Disease Background and Overview

6. Benign Prostatic Hyperplasia Patient Journey

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Benign Prostatic Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices

9. Benign Prostatic Hyperplasia Unmet Needs

10. Key Endpoints of Benign Prostatic Hyperplasia Treatment

11. Benign Prostatic Hyperplasia Marketed Products

12. Benign Prostatic Hyperplasia Emerging Therapies

13. Benign Prostatic Hyperplasia Seven Major Market Analysis

14. Attribute Analysis

15. Benign Prostatic Hyperplasia Market Outlook (7 major markets)

16. Benign Prostatic Hyperplasia Access and Reimbursement Overview

17. KOL Views on the Benign Prostatic Hyperplasia Market.

18. Benign Prostatic Hyperplasia Market Drivers

19. Benign Prostatic Hyperplasia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market

Other Trending Healthcare Reports By DelveInsight

Bacterial (Pyogenic) Meningitis Market

DelveInsight’s “Bacterial (Pyogenic) Meningitis Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, Bacterial (Pyogenic) Meningitis market size, share, trends, emerging therapies, and key companies operating in the market.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/